MedTrace Logo

Talc in Treating Patients With Malignant Pleural Effusion

NCT00002622 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 501

Last updated 2016-06-28

No results posted yet for this study

Summary

RATIONALE: Talc may relieve malignant pleural effusion. It is not yet known whether wet talc is more effective than dry talc in treating patients with malignant pleural effusion.

PURPOSE: Randomized phase III trial to compare the effectiveness of wet talc with dry talc in treating patients with malignant pleural effusion.

Conditions

Interventions

DRUG

talc

4 to 5 grams talc in 100 cc saline via chest tube at bedside, one time

DRUG

Talc

4 to 5 grams talc via insufflation through direct or video thoracoscopy, one time

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Eastern Cooperative Oncology Group

    collaborator NETWORK

  • Radiation Therapy Oncology Group

    collaborator NETWORK

  • North Central Cancer Treatment Group

    collaborator NETWORK

  • Alliance for Clinical Trials in Oncology

    lead OTHER

Principal Investigators

  • Jemi Olak, MD · Kern Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
120 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1994-12-31
Primary Completion
2005-03-31
Completion
2006-01-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00002622 on ClinicalTrials.gov